Artesunate combinations for treatment of malaria: meta-analysis (Q44728450)

5 December 2017

0 references

Artesunate combinations for treatment of malaria: meta-analysis (English)

1 reference

5 December 2017

0 references

0 references

0 references

3

1 reference

5 December 2017

0 references

M Adjuik

1

1 reference

5 December 2017

A Babiker

2

1 reference

5 December 2017

P Olliaro

4

1 reference

5 December 2017

W Taylor

5

1 reference

5 December 2017

N White

6

1 reference

5 December 2017

International Artemisinin Study Group

7

1 reference

5 December 2017

language of work or name

English

0 references

publication date

1 January 2004

1 reference

5 December 2017

1 reference

5 December 2017

363

1 reference

5 December 2017

9-17

1 reference

5 December 2017

9402

1 reference

Averting a malaria disaster

5 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915162-8

7 January 2021

Antimalarial drug resistance and combination chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915162-8

7 January 2021

Drug resistant falciparum malaria: clinical consequences and strategies for prevention.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915162-8

7 January 2021

Assessment of the pharmacodynamic properties of antimalarial drugs in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915162-8

7 January 2021

Effects of artemisinin derivatives on malaria transmissibility.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915162-8

7 January 2021

Artesunate reduces but does not prevent posttreatment transmission of Plasmodium falciparum to Anopheles gambiae.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915162-8

7 January 2021

Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915162-8

7 January 2021

Controlling malaria: challenges and solutions

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915162-8

7 January 2021

Practical methodology of meta-analyses (overviews) using updated individual patient data. Cochrane Working Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915162-8

7 January 2021

Amodiaquine-artesunate versus amodiaquine for uncomplicated Plasmodium falciparum malaria in African children: a randomised, multicentre trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915162-8

7 January 2021

Efficacy of artesunate plus pyrimethamine-sulphadoxine for uncomplicated malaria in Gambian children: a double-blind, randomised, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915162-8

7 January 2021

Sulfadoxine/pyrimethamine alone or with amodiaquine or artesunate for treatment of uncomplicated malaria: a longitudinal randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915162-8

7 January 2021

Treatment of multidrug-resistant Plasmodium falciparum malaria with 3-day artesunate-mefloquine combination.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915162-8

7 January 2021

Artesunate versus artemether in combination with mefloquine for the treatment of multidrug-resistant falciparum malaria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915162-8

7 January 2021

The use of PCR genotyping in the assessment of recrudescence or reinfection after antimalarial drug treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915162-8

7 January 2021

Methods for combining randomized clinical trials: strengths and limitations.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915162-8

7 January 2021

Why do we need systematic overviews of randomized trials?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915162-8

7 January 2021

Summing up evidence: one answer is not always enough.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915162-8

7 January 2021

10.1016/S0140-6736(03)15162-8

Identifiers

DOI

1 reference

5 December 2017

1 reference